Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer

Published:2009-10 Issue:5 Volume:32 Page:492-498
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Perez-Ellis Carole,Goncalves Anthony,Jacquemier Jocelyne,Marty Michel,Girre Véronique,Roché Henri,Brain Etienne,Moatti Jean-Paul,Viens Patrice,Le Corroller-Soriano Anne-Gaëlle

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference30 articles.

1. ERBB receptors and cancer: the complexity of targeted inhibitors.;Hynes;Nat Rev Cancer,2005

2. Humanization of an anti-p185HER2 antibody for human cancer therapy.;Carter;Proc Natl Acad Sci USA,1992

3. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.;Slamon;Science,1987

4. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.;Slamon;Science,1989

5. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment.;Marty;J Clin Oncol,2005

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews;Expert Review of Pharmacoeconomics & Outcomes Research;2020-12-01

2. A systematic review of the economic evaluations of trastuzumab in metastatic breast cancer;The Breast Journal;2020-05-07

3. Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review;PharmacoEconomics;2019-05-13

4. Nucleolar and Spindle Associated Protein 1 (NUSAP1) Inhibits Cell Proliferation and Enhances Susceptibility to Epirubicin In Invasive Breast Cancer Cells by Regulating Cyclin D Kinase (CDK1) and DLGAP5 Expression;Medical Science Monitor;2018-11-26

5. RETRACTED: Cost-utility analysis of trastuzumab combined with Docetaxel for patients with HER-2 positive metastatic breast cancer – real world claim data;Journal of Oncology Pharmacy Practice;2018-01-31